AR1001
Phase 3An oral candidate for early Alzheimer's disease that met the primary endpoint (CDR-SB) in the 604-patient monotherapy group of the global Phase 3 POLARIS-AD trial.
FROM PUBLIC EVENTS · 2026-11-18
Global approvals · expansion Has reported global Phase 3 topline results for its oral dementia candidate and signed a global rights deal with Fosun Pharma.
Roles often seen at this stageClinical & PV · Regulatory affairs · Data & AI
Develops AR1001, an oral PDE5-inhibiting candidate for Alzheimer's disease, and ran a global Phase 3 trial with 1,535 patients in 13 countries.
An oral candidate for early Alzheimer's disease that met the primary endpoint (CDR-SB) in the 604-patient monotherapy group of the global Phase 3 POLARIS-AD trial.
A long-term extension study for participants who completed 52 weeks of treatment in POLARIS-AD.
Signed an exclusive AR1001 rights deal with China's Fosun Pharma covering regions outside Korea, the Middle East and Latin America, and received $10 million of the upfront payment.
Presented POLARIS-AD topline results at CTAD 2026, with the monotherapy group meeting the primary endpoint.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.